Iovance Biotherapeutics, Inc. IOVA Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s accrued expenses and other liabilities?
- Iovance Biotherapeutics, Inc. (IOVA) reported accrued expenses and other liabilities of $88.07M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Iovance Biotherapeutics, Inc.'s accrued expenses and other liabilities increased by 4.0% year-over-year, from $84.71M to $88.07M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s accrued expenses and other liabilities?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s accrued expenses and other liabilities has grown at a 26.6% compound annual growth rate (CAGR), from $69.41M to $111.16M.